Miguel
Fernández de Sanmamed Gutiérrez
Consultor Médico
Yale University
New Haven, Estados UnidosPublications in collaboration with researchers from Yale University (10)
2023
-
CD137 (4-1BB)-Based Cancer Immunotherapy on Its 25th Anniversary
Cancer discovery, Vol. 13, Núm. 3, pp. 552-569
2021
-
A burned-out cd8+ t-cell subset expands in the tumor microenvironment and curbs cancer immunotherapy
Cancer Discovery, Vol. 11, Núm. 7, pp. 1700-1715
2020
-
Elevated serum interleukin-8 is associated with enhanced intratumor neutrophils and reduced clinical benefit of immune-checkpoint inhibitors
Nature Medicine, Vol. 26, Núm. 5, pp. 688-692
2019
-
Expression analysis and significance of PD-1, LAG-3, and TIM-3 in human non-small cell lung cancer using spatially resolved and multiparametric single-cell analysis
Clinical Cancer Research, Vol. 25, Núm. 15, pp. 4663-4673
-
Fibrinogen-like Protein 1 Is a Major Immune Inhibitory Ligand of LAG-3
Cell, Vol. 176, Núm. 1-2, pp. 334-347.e12
-
Immunotherapy in non-small cell lung cancer: Facts and hopes
Clinical Cancer Research, Vol. 25, Núm. 15, pp. 4592-4602
-
PD-1H (VISTA)–mediated suppression of autoimmunity in systemic and cutaneous lupus erythematosus
Science Translational Medicine, Vol. 11, Núm. 522
2018
-
A dormant TIL phenotype defines non-small cell lung carcinomas sensitive to immune checkpoint blockers
Nature Communications, Vol. 9, Núm. 1
2017
-
Epidermal growth factor receptor and epididymis invasion as prognostic biomarkers in clinical stage I testicular germ cell tumours
Journal of Translational Medicine, Vol. 15, Núm. 1
2014
-
Inducible expression of B7-H1 (PD-L1) and its selective role in tumor site immune modulation
Cancer Journal (United States), Vol. 20, Núm. 4, pp. 256-261